R0908
R1881
≥98% (HPLC), Androgen receptor agonist, powder
别名:
(17b)-17-羟基-17-甲基-雌甾-4,9,11-三烯-3-酮, NSC 92858, RU 1881, 甲基群勃龙, 美曲勃龙
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C19H24O2
化学文摘社编号:
分子量:
284.39
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
产品名称
R1881, ≥98% (HPLC)
SMILES string
C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CCC4=C3C=C[C@]12C
InChI key
CCCIJQPRIXGQOE-XWSJACJDSA-N
InChI
1S/C19H24O2/c1-18-9-7-15-14-6-4-13(20)11-12(14)3-5-16(15)17(18)8-10-19(18,2)21/h7,9,11,16-17,21H,3-6,8,10H2,1-2H3/t16-,17+,18+,19+/m1/s1
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -48 to -68°
drug control
USDEA Schedule IIIN; Home Office Schedule 4.2; regulated under CDSA - not available from Sigma-Aldrich Canada
color
light yellow to yellow
solubility
DMSO: ≥10 mg/mL
storage temp.
2-8°C
Quality Level
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
涉药品监管产品
此项目有
Juliet Richards et al.
Cancer research, 72(9), 2176-2182 (2012-03-14)
Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an antiandrogen. Abiraterone, a rationally designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC), is often effective
Nader Al Nakouzi et al.
European urology, 68(2), 228-235 (2014-05-20)
Cabazitaxel, abiraterone acetate (AA), and enzalutamide have been approved for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel chemotherapy. Whether taxanes and next-generation androgen receptor (AR) axis inhibitors are cross-resistant or not is a subject of
Robert S Hudson et al.
Molecular cancer, 12, 13-13 (2013-02-16)
Ultraconserved regions (UCR) are genomic segments of more than 200 base pairs that are evolutionarily conserved among mammalian species. They are thought to have functions as transcriptional enhancers and regulators of alternative splicing. Recently, it was shown that numerous RNAs
Liyuan Yin et al.
Scientific reports, 10(1), 1216-1216 (2020-01-29)
Advanced and therapy-resistant prostate tumors often display neural or neuroendocrine behavior. We assessed the consequences of prostate cancer cell interaction with neural cells, which are rich in the human prostate and resident of the prostate tumor. In 3-dimensional co-culture with
Lingyan Jin et al.
Cancer research, 77(20), 5564-5575 (2017-08-19)
Resistance invariably develops to antiandrogen therapies used to treat newly diagnosed prostate cancers, but effective treatments for castration-resistant disease remain elusive. Here, we report that the transcriptional coactivator CBP/p300 is required to maintain the growth of castration-resistant prostate cancer. To
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持